Graft Versus Host Disease (GVHD)

Steroid-refractory GvHD (SR-GvHD) following allogeneic transplant is a major clinical challenge and is associated with substantial mortality [1]. While the European Society for Bone and Marrow Transplantation (EBMT) recommends ruxolitinib for second-line treatment of GvHD [2]…

Abstract Purpose Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for advanced hematologic malignancies. HSCT using human leukocyte antigen (HLA)-mismatched donors is historically associated with inferior survival. Patients from underrepresented…

Key Points Prolonged ruxolitinib administration after allogeneic HCT is associated with low rates of clinically significant chronic GVHD. Abstract Despite recent advances in graft-versus-host disease (GVHD) prophylaxis, novel approaches to effective prevention of chronic GVHD…

Cyclophosphamide plus cyclosporin, a calcineurin inhibitor, significantly improved graft-vs-host disease (GVHD)–free relapse-free survival (RFS) compared with standard prophylaxis in patients with aggressive blood cancers who are undergoing stem cell transplant from a matched…

Key Points Treg-engineered donor graft prevents acute and chronic GVHD. Patients treated with Treg-engineered graft who develop GVHD respond to primary corticosteroid therapy at a high rate. Abstract Allogeneic hematopoietic cell transplantation is a curative therapy limited by…

Abstract The role of ABO blood group system mismatch on allogeneic hematopoietic cell transplantation (allo-HCT) outcomes is controversial since current publications of large datasets are lacking. We retrospectively analyzed 30,487 patients transplanted between 2010 and 2021…